These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 34289398)

  • 1. The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
    Bjornstad P; Greasley PJ; Wheeler DC; Chertow GM; Langkilde AM; Heerspink HJL; Van Raalte DH
    J Card Fail; 2021 Dec; 27(12):1447-1455. PubMed ID: 34289398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
    Packer M; Wilcox CS; Testani JM
    Circulation; 2023 Jul; 148(4):354-372. PubMed ID: 37486998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.
    Packer M; Butler J
    Eur J Heart Fail; 2023 Sep; 25(9):1537-1543. PubMed ID: 37403655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology.
    van Ruiten CC; Hesp AC; van Raalte DH
    Eur J Intern Med; 2022 Jun; 100():13-20. PubMed ID: 35414444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors.
    Vardeny O
    Am J Med; 2020 Feb; 133(2):182-185. PubMed ID: 31494110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.
    Perry RJ; Shulman GI
    J Biol Chem; 2020 Oct; 295(42):14379-14390. PubMed ID: 32796035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
    Ojha U; Reyes L; Eyenga F; Oumbe D; Watkowska J; Saint-Jacques H
    Am J Cardiovasc Drugs; 2022 Jan; 22(1):35-46. PubMed ID: 34189716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients.
    Kubica J; Kubica A; Grzelakowska K; Stolarek W; Grąbczewska Z; Michalski P; Niezgoda P; Bartuś S; Budaj A; Dąbrowski M; Drożdż J; Gellert R; Jaguszewski MJ; Jankowski P; Legutko J; Lesiak M; Leszek P; Małyszko J; Mitkowski P; Nessler J; Pawlaczyk K; Siller-Matula J; Stompór T; Wolnik B; Navarese EP
    Cardiol J; 2023; 30(1):143-149. PubMed ID: 34708866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure.
    Packer M
    Cardiovasc Diabetol; 2023 Aug; 22(1):197. PubMed ID: 37533009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease.
    Chan JSK; Perone F; Bayatpoor Y; Tse G; Harky A
    Expert Opin Pharmacother; 2023 Jun; 24(8):935-945. PubMed ID: 37070470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature.
    McKenzie T; Hale GM; Miner A; Colón Colón J; Evins G; Wade J
    Heart Fail Rev; 2024 Mar; 29(2):549-558. PubMed ID: 38300379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
    Filippatos TD; Liontos A; Papakitsou I; Elisaf MS
    Postgrad Med; 2019 Mar; 131(2):82-88. PubMed ID: 30757937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
    Hallow KM; Helmlinger G; Greasley PJ; McMurray JJV; Boulton DW
    Diabetes Obes Metab; 2018 Mar; 20(3):479-487. PubMed ID: 29024278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.